Isabel Rauscher Selected Research

Therapeutics

4/2024	RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
1/2024	A Clinical Role of PET-MRI in Prostate Cancer?
11/2023	Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.
1/2023	Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
1/2023	Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
1/2023	177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
1/2023	SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.
1/2023	The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
11/2022	Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
10/2022	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabel Rauscher Research Topics

Disease

57	Prostatic Neoplasms (Prostate Cancer) 05/2024 - 01/2016
20	Neoplasms (Cancer) 01/2024 - 01/2016
7	Neoplasm Metastasis (Metastasis) 01/2023 - 12/2017
3	Lymphatic Metastasis 01/2021 - 11/2016
2	Disease Progression 01/2023 - 10/2019
2	Pain (Aches) 01/2017 - 01/2016
1	Margins of Excision 08/2021
1	Adenocarcinoma 07/2021
1	Carcinoma (Carcinomatosis) 12/2020
1	Seminoma 11/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2018
1	Multiple Myeloma 07/2017
1	Autoimmune Pancreatitis 01/2017
1	Stress Fractures (Stress Fracture) 12/2015
1	Liver Cirrhosis (Hepatic Cirrhosis) 06/2014

Drug/Important Bio-Agent (IBA)

34	AntigensIBA 04/2024 - 01/2016
21	LigandsIBA 11/2023 - 01/2016
14	gallium 68 PSMA-11IBA 01/2023 - 06/2016
8	Prostate-Specific Antigen (Semenogelase)IBA 01/2023 - 01/2016
7	PSMA I&TIBA 05/2024 - 01/2016
5	N,N'- bis(2- hydroxy- 5- (ethylene- beta- carboxy)benzyl)ethylenediamine N,N'-diacetic acidIBA 07/2017 - 09/2016
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2014
2	Hormones (Hormone)IBA 01/2023 - 05/2021
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 07/2021 - 01/2017
2	Radioisotopes (Radionuclides)IBA 10/2020 - 01/2020
2	Choline (Choline Chloride)IBA 11/2018 - 12/2017
1	RadiopharmaceuticalsIBA 04/2024
1	taxaneIBA 01/2023
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2023
1	Alkaline PhosphataseIBA 01/2023
1	Gallium-68IBA 01/2021
1	A-factor (Streptomyces)IBA 01/2021
1	AndrogensIBA 12/2019
1	Deoxyglucose (2 Deoxy D glucose)IBA 11/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	GalliumIBA 11/2016
1	Androgen Receptors (Androgen Receptor)IBA 01/2016

Therapy/Procedure

19	Therapeutics 04/2024 - 01/2016
16	Castration 05/2024 - 01/2016
15	Prostatectomy (Retropubic Prostatectomy) 01/2023 - 05/2016
10	Lymph Node Excision (Lymph Node Dissection) 01/2023 - 05/2016
7	Drug Therapy (Chemotherapy) 01/2023 - 01/2016
4	Radiotherapy 01/2022 - 01/2017
3	Precision Medicine 01/2024 - 01/2021
2	Brachytherapy 01/2022 - 01/2017
2	Salvage Therapy 06/2021 - 03/2021
1	Combined Modality Therapy 11/2022
1	Intravenous Injections 01/2019
1	Conservative Treatment 12/2015